Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Seqirus Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (106)
Cancellation by sponsor (27)
Prescription medicine registration (19)
Australian Public Assessment Report (AusPAR) (13)
Section 14, TGO91 consent (3)
Designation or determination (2)
Prescription medicine decision summary (2)
Prescription medicine evaluation (2)
Cancellation or suspension (1)

Date

2026 (21)
2025 (14)
2024 (3)
2023 (6)
2022 (8)
2021 (6)
2020 (28)
2019 (12)
2018 (19)
2017 (6)
2016 (2)
2015 (1)
2014 (3)
2011 (7)
2010 (3)
2009 (5)
2008 (1)
2006 (3)
2005 (1)
2004 (4)
2003 (1)
2002 (1)
2000 (13)
1998 (3)
1991 (4)

Search

Sponsor content

175 result(s) found, displaying 111 to 120

XADAGO (Seqirus Pty Ltd)

30 October 2018

Prescription medicine registration

Active ingredients: safinamide mesilate.
AU D00320, AU D00336, AU D00492 (Revocation of a TGA certificate under section 41ES of the Therapeutic Goods Act 1989.)

22 June 2018

Cancellation or suspension

Regulatory action due to Voluntary revocation at the request of the manufacturer., effective 22/06/2018
ACARIZAX (Seqirus Pty Ltd)

25 May 2018

Prescription medicine registration

Active ingredients: American house dust mite extract, European house dust mite extract.
Seqirus Pty Ltd - Reagent red blood cell IVDs Cancelled under Section 41GL(d) of the Act

30 April 2018

Cancellation by sponsor

Requested by Seqirus Pty Ltd
Seqirus Pty Ltd - Reagent red blood cell IVDs Cancelled under Section 41GL(d) of the Act

30 April 2018

Cancellation by sponsor

Requested by Seqirus Pty Ltd
Seqirus Pty Ltd - Immunohaematology calibrator/control IVDs Cancelled under Section 41GL(d) of the Act

30 April 2018

Cancellation by sponsor

Requested by Seqirus Pty Ltd
Seqirus Pty Ltd - Immunohaematology calibrator/control IVDs Cancelled under Section 41GL(d) of the Act

30 April 2018

Cancellation by sponsor

Requested by Seqirus Pty Ltd
Seqirus Pty Ltd - Immunohaematology sensitised cell-typing IVDs Cancelled under Section 41GL(d) of the Act

30 April 2018

Cancellation by sponsor

Requested by Seqirus Pty Ltd
Seqirus Pty Ltd - Immunohaematology blood grouping antisera IVDs Cancelled under Section 41GL(d) of the Act

30 April 2018

Cancellation by sponsor

Requested by Seqirus Pty Ltd
Seqirus Pty Ltd - Immunohaematology blood grouping antisera IVDs Cancelled under Section 41GL(d) of the Act

30 April 2018

Cancellation by sponsor

Requested by Seqirus Pty Ltd

Pages

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Current page 12
Page 13
Page 14
Page 15
Page 16
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.